In a patient taking phenytoin (Dilantin) 150 mg twice daily, lacosamide 200 mg twice daily, and levetiracetam (Keppra) 1500 mg twice daily, what oral antiepileptic can replace phenytoin during a Dilantin shortage?

Replacement Options for Phenytoin During Shortage

In a patient on phenytoin 150 mg BID with lacosamide 200 mg BID and levetiracetam 1500 mg BID, increase the levetiracetam dose to replace phenytoin, or add valproate as a third adjunctive agent if seizure control requires additional coverage.

Primary Recommendation: Increase Levetiracetam

Since this patient is already on levetiracetam (Keppra) 1500 mg BID (3000 mg/day total), you have room to optimize this medication before adding another agent:

• Current levetiracetam dose: 3000 mg/day is the typical maximum recommended daily dose 1
• However, levetiracetam has been safely loaded and used at doses up to 60 mg/kg IV 1, and the patient may tolerate dose escalation
• Consider increasing to: 2000 mg BID (4000 mg/day total) if seizure control becomes problematic after phenytoin discontinuation
• Advantages: Already on this medication, excellent safety profile, no drug interactions with existing lacosamide 2, minimal adverse effects compared to enzyme-inducing agents 3

Alternative: Add Valproate

If additional antiepileptic coverage is needed beyond optimizing levetiracetam:

Valproate is the preferred alternative replacement 1:

• Dosing: Start 500-750 mg BID orally, titrate to effect (typical range 1000-2000 mg/day divided BID)
• Evidence: Valproate demonstrated equal or superior efficacy to phenytoin in multiple studies, with 88% seizure control rates versus 84% for phenytoin 1
• Safety advantage: No hypotension risk compared to IV phenytoin (12% hypotension with phenytoin vs 0% with valproate) 1
• Drug interactions: Check for interactions but generally well-tolerated with levetiracetam and lacosamide 1

Why NOT These Options:

Fosphenytoin

• Simply a prodrug of phenytoin; if there's a Dilantin shortage, fosphenytoin may also be unavailable or in short supply
• Same mechanism of action, so doesn't add therapeutic diversity

Lamotrigine

• Requires slow titration over several weeks to avoid serious rash risk 3
• Not appropriate for acute replacement during a shortage
• Only consider if long-term transition is planned with adequate time

Phenobarbital

• Significant adverse effect profile including respiratory depression and hypotension 1
• Not recommended as first choice given better alternatives available 3

Additional Lacosamide

• Patient already on 200 mg BID (400 mg/day)
• Maximum recommended dose is typically 400 mg/day
• Caution: Abrupt discontinuation can cause withdrawal seizures 1
• Limited room for dose escalation

Critical Caveats:

Avoid enzyme-inducing anticonvulsants (carbamazepine, phenobarbital) as they are explicitly not recommended due to drug interactions and side-effect profiles 3

Taper phenytoin gradually if possible (over 1-2 weeks) while introducing replacement therapy to avoid breakthrough seizures from abrupt discontinuation

Monitor closely for the first 2-4 weeks after transition for breakthrough seizures or adverse effects from dose adjustments

Check drug levels of existing medications if seizure control worsens, as compliance and absorption issues may be contributing factors

The evidence strongly supports that levetiracetam and valproate are equally effective alternatives to phenytoin 1, with levetiracetam having the advantage of already being part of this patient's regimen and valproate offering proven efficacy with fewer cardiovascular adverse effects than phenytoin.